Session 163 - CROI 2007

Session 163 Poster Abstracts
Effects of ART on Liver Disease in HBV or HCV Co-Infected Persons
Tuesday, 1 - 4 pm
Poster Hall

930	Risk Factors for Advanced Liver Fibrosis and High Level of Necroinflammatory Activity in HIV/HCV Co-infected Patients Receiving ART J Pascual-Pareja, A Caminoa, J Arribas, J Larrauri, Juan Gonzalez García*, M López-Dieguez, M Montes, O Madridano, and J Vazquez-Rodriguez Hosp La Paz, Madrid, Spain
931	Faster Progression of Liver Fibrosis in Chronic Hepatitis Due to HCV than to HVB in HIV⁺ Patients in the Tenofovir Era C Castellares,*, L Martin-carbonero, P Barreiro, M Nuñez, B Ramos, J Sheldon, L Galindo, R Casado, J González-lahoz, and V Soriano Hosp Carlos III, Madrid, Spain
932	Increased Progression to Liver Disease and Death in HIV/HCV than in HBV-co-infected Patients Colette Smit*¹, L Gras¹, A van Sighem¹, T Ruys², J Lange², F de Wolf^1,3, and F de Wolf^1,3 ¹HIV Monitoring Fndn, Academic Med Ctr, Univ of Amsterdam, The Netherlands; ²Ctr for Immunity and Infection, Academic Med Ctr, Univ of Amsterdam, The Netherlands; and ³Imperial Coll Sch of Med, London, UK
933	Comparison of Triple Infection with HIV/HBV/HCV to HIV/HCV and HIV/HBV Mamta Jain*, R Joshi, N Attar, P Keiser, and W Lee Univ of Texas Southwestern Med Ctr, Dallas, US
934	Clinical Progression of Hepatitis C Virus-related Chronic Liver Disease in HIV-infected Patients Undergoing HAART José A. García-García*¹, M Aguilar-Guisado², M Ríos-Villegas³, M González-Serrano⁴, A Rivero⁵, J Del Valle¹, R Luque², J Ruiz-Morales⁴, J Macías¹, J Pineda¹, and Grupo Andaluz para el Estudio de las Enfermedades Infecciosas (GAEI) ¹Hosp Univ de Valme, Seville, Spain; ²Hosp Univ Virgen del Rocio, Seville, Spain; ³Hosp Univ Virgen de la Macarena, Seville, Spain; ⁴Hosp Virgen de la Victoria, Malaga, Spain; and ⁵Hosp Univ Reina Sofía, Cordoba, Spain
935	HAART Reduces the Fibrosis Progression Rate and the Development of Bridging Fibrosis and Cirrhosis in HIV/HCV-co-infected Patients S Resino, Juan Berenguer*, P Miralles, J Bellón, M Sánchez-Conde, J López, J Cosín, B Padilla, P Catalán, and E Álvarez Hosp Gregorio Maranon, Madrid, Spain
936	Progression after Initiating ART Combination Therapy in HIV/HCV-co-infected Patients According to Different Baseline CD4⁺ Cell Count Strata Fernando Dronda*, J Zamora, C Quereda, J Hermida, J Casado, B Hernandez, M Perez-Elias, A Moreno, and S Moreno Hosp Ramon y Cajal, Madrid, Spain
937	Factors Associated with High HCV Viral Load in HIV/HCV Co-infected Patients: Is There a Different Effect between PI and Non-PI-based ART? Firouze Bani-Sadr*¹, I Goderel¹, P Morand², F Lunel-Fabiani³, C Payan³, P Cacoub⁴, S Pol⁵, C Perronne⁶, F Carrat¹, and ANRS HC02 – Ribavic Study team ¹Groupe Hosp Univ Est, Univ Paris 6, INSERM U707, France; ²Ctr Hosp Univ Grenoble, France; ³Ctr Hosp Univ Angers, France; ⁴Groupe Hosp Univ Est, Univ Paris 6, France; ⁵Groupe Hosp Univ Ouest, Univ Paris 5, INSERM U567, France; and ⁶Ctr Hosp Univ Raymond Poincare, Univ de Versailles, Garches
938	Risk Factors for Liver Enzymes Elevation in HIV/HBV-co-Infected Patients: Impact of ART O Chauvel^1,2, O Chauvel^1,2, Karine Lacombe^1,2, Karine Lacombe^1,2, G Pialoux³, C Lascoux-Combe⁴, J M Molina⁴, P Miailhes⁵, P M Girard¹, F Carrat^1,2, and F Carrat^1,2 ¹Hosp St Antoine, Paris, France; ²INSERM U707, Univ Pierre and Marie Curie, Paris, France; ³Hosp Tenon, Paris, France; ⁴Hosp St Louis, Paris, France; and ⁵Hotel-Dieu, Lyon, France
939	Long-term Efficacy of Combination Lamivudine + Tenofovir Therapy in Chronic HIV/HBV-co-infected Patients T.E.M.S. de Vries-Sluijs*, R de Man, M Schutten, G van Doornum, and M van der Ende Erasmus Med Ctr, Rotterdam, The Netherlands
940	Occult Hepatitis B Viremia in HIV-infected Individuals on 3TC-containing ART and Its Relationship to Immunologic Status Debika Bhattacharya*¹, D Katzenstein², D Israelski³, L P Shen⁴, C Wong⁴, C Bush⁴, and R Donovan⁵ ¹David Geffen Sch of Med, Univ of California, Los Angeles, US; ²Stanford Univ, CA, US; ³San Mateo Clin AIDS Prgm, CA, US; ⁴Bayer Diagnostics, Berkeley, CA, US; and ⁵California Dept of Hlth Svcs, Richmond, US
941	Evolution of Hepatitis B Virus Serological Markers in HIV-infected Persons Receiving HAART W H Sheng, Chien-Ching Hung*, and S C Chang Natl Taiwan Univ Hosp, Taipei
942	Surveillance of Hepatitis B Virus Mutations during Tenofovir Treatment in HIV/HBV-co-infected Individuals Jennifer Audsley^1,2,3, Jennifer Audsley^1,2,3, Jennifer Audsley*^1,2,3, N Arrafin¹, L Yuen⁴, A Ayres⁴, S Crowe⁵, A Bartholomeusz⁴, S Locarnini⁴, A Mijch¹, S Lewin^1,2,3, S Lewin^1,2,3, S Lewin^1,2,3, J Sasadeusz^1,3,6, J Sasadeusz^1,3,6, and J Sasadeusz^1,3,6 ¹Alfred Hosp, Melbourne, Australia; ²Monash Univ, Melbourne, Australia; ³Ctr for Clin Res Excellence in Infectious Diseases, Univ of Melbourne, Australia; ⁴Victorian Infectious Diseases Reference Lab, North Melbourne, Australia; ⁵The Burnet Inst, Melbourne, Australia; and ⁶Victorian Infectious Diseases Svc, Melbourne, Australia
943	Prevalence and Clinical Relevance of Occult Hepatitis B in the Fibrosis Progression and Antiviral Response to INF Therapy in HIV/HVC-co-infected Patients M Laguno, M Larrouse, A Leon, A Milinkovic, J Blanco, M Loncá, E Martínez, E de Lazzari, J Gatell, and Josep Mallolas* Hosp Clin, Barcelona, Spain
944	Hepatitis B Surface Antigen Seroreversion in HIV Patients in the Era of HAART: A Population Profile S Aitchison, Anne Mijch*, J Yu, and K Watson Victorian HIV Svc, Alfred Hosp, Prahran, Victoria, Australia